Patent ID: 8945545
Filing Date: 2015-02-03
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, for a first extended period of at least about 4 weeks, wherein the subject achieves at least a Psoriasis Area and Severity Index (PASI) 75 response by at least about week 12 following initial administration of the antibody, or antigen-binding portion thereof, discontinuing administration of the antibody, or antigen-binding portion thereof, for at least about 12 weeks following the first extended period of administration, wherein the subject exhibits a loss of response by a decrease in PASI score to less than PASI 50 following discontinuation, and re-administering the antibody, or antigen-binding portion thereof, to the subject for a second extended period of at least about 4 weeks, wherein the subject achieves at least a PASI 75 response by at least about 60 days following re-administration of the antibody, or antigen-binding portion thereof, thereby treating psoriasis in the subject.